New product: Adakveo (crizanlizumab) 10 mg/ml concentrate for solution for infusion
This is licensed for prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell disease patients aged ≥16 years. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.
Source:
electronic Medicines compendium
SPS commentary:
Crizanlizumab is a selective IgG2 kappa humanised monoclonal antibody that binds to P-selectin with high affinity and blocks the interaction with its ligands, including P-selectin glycoprotein ligand. In recent DRAFT NICE guidance, crizanlizumab is recommended as an option for preventing recurrent sickle cell crises (vaso-occlusive crises) in people aged 16 or over with sickle cell disease contingent on the conditions in the managed access agreement being followed.